Every year, more than 2000 New Zealand women are diagnosed with oestrogen receptor positive breast cancer. Most of these women are treated with therapies that target production or action of the hormone oestrogen. However, some patients obtain little to no benefit from this treatment and their cancer returns. We have previously found that women with high levels of immune cells within their tumours have poorer outcomes. To find ways to improve the response of these tumours to therapy, we aim to trial a short treatment of the common anti-inflammatory drug aspirin together with standard anti-oestrogen therapy.
We will determine whether administering these two drugs together will decrease the number of immune cells entering the tumour and the rate at which the tumour grows. This analysis will indicate whether aspirin is likely to help patients longer term and define biomarkers to identify which patients are in greatest need of additional therapies.
The study identified approximately 500 genes that may act in this way, with 14 that appear to have a very significant effect. We are now working with leading research institutions around the world to determine whether measuring the level of activity of these genes in tumour samples taken from breast cancer patients may enable us to predict whether each individual is likely to benefit from trastuzumab emtansine. In parallel, we are investigating whether our findings may help to inform better treatment of HER2-amplified breast cancer in such a way that avoids resistance to trastuzumab emtansine or ameliorates it if it does arise.
FIRST NAMED INVESTIGATOR: Dr Anita Dunbier
HOST INVESTIGATOR: Dr Anita Dunbier